Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.480
+0.020 (0.58%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Eledon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 16.98 | 18.61 | 12.69 | 13.1 | 13.43 | |
| Research & Development | 66.27 | 51.96 | 30.31 | 26.68 | 23.44 | |
| Operating Expenses | 83.25 | 70.58 | 43 | 39.78 | 36.87 | |
| Operating Income | -83.25 | -70.58 | -43 | -39.78 | -36.87 | |
| Other Non Operating Income (Expenses) | 37.67 | 34.82 | -73.54 | 0.46 | 0.01 | |
| EBT Excluding Unusual Items | -45.58 | -35.75 | -116.54 | -39.32 | -36.86 | |
| Impairment of Goodwill | - | - | - | -48.65 | - | |
| Pretax Income | -45.58 | -35.75 | -116.54 | -87.97 | -36.86 | |
| Income Tax Expense | 0.04 | 0.43 | - | - | -2.35 | |
| Net Income | -45.62 | -36.18 | -116.54 | -87.97 | -34.51 | |
| Net Income to Common | -45.62 | -36.18 | -116.54 | -87.97 | -34.51 | |
| Shares Outstanding (Basic) | 82 | 49 | 25 | 14 | 15 | |
| Shares Outstanding (Diluted) | 82 | 49 | 25 | 14 | 15 | |
| Shares Change (YoY) | 68.42% | 97.64% | 72.34% | -3.61% | 921.03% | |
| EPS (Basic) | -0.56 | -0.74 | -4.73 | -6.16 | -2.33 | |
| EPS (Diluted) | -0.56 | -0.74 | -4.73 | -6.16 | -2.33 | |
| Free Cash Flow | -62.34 | -47.27 | -39.53 | -28.42 | -28.91 | |
| Free Cash Flow Per Share | -0.76 | -0.97 | -1.61 | -1.99 | -1.95 | |
| EBITDA | - | - | - | - | -36.86 | |
| D&A For EBITDA | - | - | - | - | 0.01 | |
| EBIT | -83.25 | -70.58 | -43 | -39.78 | -36.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.